组胺HR1拮抗剂对变应性鼻炎IL-12及DCs的影响

Effect of HR1 antagon on IL-12 and DCs in allergic rhinitis

目的:通过观察组胺HR1拮抗剂干预后对变应性鼻炎(AR)大鼠血清中IL-12,以及鼻黏膜中树突状细胞(DCs)的变化和影响,并探讨其作用机制.方法:实验大鼠随机分为正常对照组,AR无干预组,ARHR1拮抗剂干预组,观察致敏以及组胺HR1拮抗剂干预后大鼠血清IL-12含量及鼻黏膜中DCs数量的变化.结果:与正常对照组相比,AR无干预组血清IL-12含量下降(P<0.01),鼻黏膜中DCs数量则增加(P<0.01);而ARHR1拮抗剂干预组经组胺HR1拮抗剂干预后,血清IL-12含量回升(P=0.042),鼻黏膜中DCs数量则下降(P=0.003).结论:AR时IL-12含量减少以及DCs数量增加是AR发病的重要因素;组胺HR1拮抗剂可以抑制IL-12,DCs的变化,是其在AR治疗中发挥作用的机制之一.

AIM： To approach the influence of HR1 antagon on IL-12 and DCs, and to get the message about their roles in allergic rhinitis（AR）. METHODS ： Rats were divided into 3 groups ： Normal control group, AR group, AR ＋ HR1 antagon group. The serum levels of IL-12 and DCs in nasal mucosa were observed in 3 groups. RESULTS： Serum IL-12 level in AR group decreased significantly compared with normal control group（P 〈0.01 ） , but DCs number in nasal mucosa increased （ P 〈 0.01 ） ; After HR1 antagon treatment, serum IL-12 level turned back （P = 0. 042 ）, at the same time, DCs number in nasal mucosa was reduced（P = 0.003）. CONCLUSION： It may be an important pathogenetic factor that IL-12 level decreases and DCs number in nasal mucosa increases in AR. HR1 antagon could suppress this change, which may explain the curative action of HR1 antagon on AR.